Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Rxo (RXO) Cost of Revenue (2021 - 2025)

Rxo's Cost of Revenue history spans 5 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 11.35% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $4.6 billion, up 29.34%, while the annual FY2025 figure was $4.6 billion, 29.34% up from the prior year.
  • Cost of Revenue reached $1.2 billion in Q4 2025 per RXO's latest filing, up from $1.1 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.4 billion in Q4 2024 to a low of $699.0 million in Q1 2024.
  • Average Cost of Revenue over 5 years is $932.0 million, with a median of $880.5 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: decreased 25.66% in 2023, then surged 82.64% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $1.1 billion in 2021, then decreased by 19.89% to $842.0 million in 2022, then decreased by 11.76% to $743.0 million in 2023, then surged by 82.64% to $1.4 billion in 2024, then dropped by 11.35% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for RXO's Cost of Revenue are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).